| A smart and versatile theranostic nanomedicine platform based on nanoporphyrin Y Li, T Lin, Y Luo, Q Liu, W Xiao, W Guo, D Lac, H Zhang, C Feng, ... Nature communications 5 (1), 4712, 2014 | 426 | 2014 |
| Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients L Cheng, CX Pan, XJ Yang, A Lopez‐Beltran, GT MacLennan, H Lin, ... Cancer 101 (5), 957-962, 2004 | 386 | 2004 |
| From combinatorial chemistry to cancer-targeting peptides OH Aina, R Liu, JL Sutcliffe, J Marik, CX Pan, KS Lam Molecular pharmaceutics 4 (5), 631-651, 2007 | 376 | 2007 |
| Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy M Wang, LC Yao, M Cheng, D Cai, J Martinek, CX Pan, W Shi, AH Ma, ... The FASEB Journal 32 (3), 1537, 2018 | 304 | 2018 |
| Combination strategies to maximize the benefits of cancer immunotherapy S Zhu, T Zhang, L Zheng, H Liu, W Song, D Liu, Z Li, C Pan Journal of hematology & oncology 14 (1), 156, 2021 | 276 | 2021 |
| Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised … DP Petrylak, R De Wit, KN Chi, A Drakaki, CN Sternberg, H Nishiyama, ... The Lancet 390 (10109), 2266-2277, 2017 | 239 | 2017 |
| CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy K Pan, H Farrukh, VCSR Chittepu, H Xu, C Pan, Z Zhu Journal of Experimental & Clinical Cancer Research 41 (1), 119, 2022 | 226 | 2022 |
| Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma L Cheng, TD Jones, RP McCarthy, JN Eble, M Wang, GT MacLennan, ... The American journal of pathology 166 (5), 1533-1539, 2005 | 225 | 2005 |
| Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen‐independent status H Hong, C Kao, MH Jeng, JN Eble, MO Koch, TA Gardner, S Zhang, L Li, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2004 | 224 | 2004 |
| Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group CW Ryan, BH Goldman, PN Lara Jr, PC Mack, TM Beer, CM Tangen, ... Journal of clinical oncology 25 (22), 3296-3301, 2007 | 198 | 2007 |
| Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy C Pan, H Liu, E Robins, W Song, D Liu, Z Li, L Zheng Journal of hematology & oncology 13 (1), 29, 2020 | 193 | 2020 |
| High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia G Zeng, Z Hu, MS Kinch, CX Pan, DA Flockhart, C Kao, TA Gardner, ... The American journal of pathology 163 (6), 2271-2276, 2003 | 158 | 2003 |
| Anatomic distribution and pathologic characterization of small-volume prostate cancer (< 0.5 ml) in whole-mount prostatectomy specimens L Cheng, TD Jones, CX Pan, A Barbarin, JN Eble, MO Koch Modern Pathology 18 (8), 1022-1026, 2005 | 151 | 2005 |
| Thyroid transcription factor 1 expression in small cell carcinoma of the urinary bladder: an immunohistochemical profile of 44 cases TD Jones, KM Kernek, XJ Yang, A Lopez-Beltran, GT MacLennan, ... Human pathology 36 (7), 718-723, 2005 | 142 | 2005 |
| MiR‐34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53‐Rb pathway status RL Vinall, AZ Ripoll, S Wang, CX Pan, RW deVere White International journal of cancer 130 (11), 2526-2538, 2012 | 135 | 2012 |
| Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317 MS Gordon, M Hussey, RB Nagle, PN Lara Jr, PC Mack, J Dutcher, ... Journal of Clinical Oncology 27 (34), 5788, 2009 | 135 | 2009 |
| Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival Y Wang, M Mikhailova, S Bose, CX Pan, RWV White, PM Ghosh Oncogene 27 (56), 7106-7117, 2008 | 117 | 2008 |
| Loss of 14-3-3σ in prostate cancer and its precursors L Cheng, CX Pan, JT Zhang, S Zhang, MS Kinch, L Li, LA Baldridge, ... Clinical Cancer Research 10 (9), 3064-3068, 2004 | 115 | 2004 |
| Molecular genetic alterations in the laser‐capture–microdissected stroma adjacent to bladder carcinoma RF Paterson, TM Ulbright, GT MacLennan, S Zhang, CX Pan, ... Cancer 98 (9), 1830-1836, 2003 | 113 | 2003 |
| The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial KG Chee, J Longmate, DI Quinn, G Chatta, J Pinski, P Twardowski, ... Clinical genitourinary cancer 5 (7), 433-437, 2007 | 112 | 2007 |
